Intranasal Administration of Nicotinamide Adenine Dinucleotide Alleviates Headaches Associated with Migraine Pain: A Case Report
Thompson, A., DiBlasio, P., Dyess, G.A., Broom, S.L., Mestayer, R.F, presented at Mississippi Academy of Sciences Conference, March 2022
An 87-year-old woman with a 50-year history of migraines received NAD/Lidocaine at 100 mg/mL, 0.5% per protocol of 0.5 mL, intranasally into each nostril via sphenocatheter. The patient also was prescribed Real NAD+ (150mg/day) sublinguql lozenges over a three-month period.
Follow-up interviews were conducted at one week, six weeks, three months, and one year, with the following results:
The patient tolerated the treatment well, reported no adverse effects, and has not had a single recurring migraine.